IDO1 and myeloid sarcoma: In addition to immunosuppressive Trp metabolites, cells expressing IDO1 may produce neuroactive Trp metabolites that exacerbate comorbidities such as pain, depression, and fatigue in patients with MS and other neuroinflammatory syndromes (36–38).